Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126950026 | 12695002 | 6 | F | 201407 | 20160913 | 20160829 | 20160921 | EXP | PHJP2016JP023955 | SANDOZ | MORITA R, UCHIDA S, TAKADA A, MATSUDA H, OISO N, KAWADA A. EFFECTIVENESS OF PERIODIC INTRAVENOUS IMMUNOGLOBULIN THERAPY IN A PATIENT WITH PEMPHIGUS VULGARIS. SKIN RESEARCH/J1605403. 2016;15(3):119-24 | 66.00 | YR | F | Y | 41.50000 | KG | 20160921 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126950026 | 12695002 | 1 | PS | NEORAL | CYCLOSPORINE | 1 | Unknown | 120 MG, QD | D | 0 | 120 | MG | CAPSULE | QD | |||||
| 126950026 | 12695002 | 2 | SS | NEORAL | CYCLOSPORINE | 1 | Unknown | 100 MG, QD | D | 0 | 100 | MG | CAPSULE | QD | |||||
| 126950026 | 12695002 | 3 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 60 MG, QD | D | 0 | 60 | MG | QD | ||||||
| 126950026 | 12695002 | 4 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 50 MG, QD | D | 0 | 50 | MG | QD | ||||||
| 126950026 | 12695002 | 5 | SS | METHYLPREDNISOLONE SODIUM SUCCINATE. | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Unknown | 1 G/DAY FOR 3 DAYS (ONE COURSE) | D | 0 | 1 | G | QD | ||||||
| 126950026 | 12695002 | 6 | SS | BETAMETHASONE. | BETAMETHASONE | 1 | Unknown | 5 MG, QD | D | 0 | 5 | MG | QD | ||||||
| 126950026 | 12695002 | 7 | SS | BETAMETHASONE. | BETAMETHASONE | 1 | Unknown | 4.5 MG, QD | D | 0 | 4.5 | MG | QD | ||||||
| 126950026 | 12695002 | 8 | SS | BETAMETHASONE. | BETAMETHASONE | 1 | Unknown | 1.5 MG, QD | D | 0 | 1.5 | MG | QD | ||||||
| 126950026 | 12695002 | 9 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Unknown | 24 MG, QD | D | 0 | 24 | MG | QD | ||||||
| 126950026 | 12695002 | 10 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Unknown | 16 MG, QD | D | 0 | 16 | MG | QD | ||||||
| 126950026 | 12695002 | 11 | C | KENKETU GLOVENIN-I | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 400 MG/KG, QD | D | 0 | 400 | MG/KG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126950026 | 12695002 | 1 | Pemphigus |
| 126950026 | 12695002 | 3 | Pemphigus |
| 126950026 | 12695002 | 5 | Pemphigus |
| 126950026 | 12695002 | 6 | Pemphigus |
| 126950026 | 12695002 | 9 | Pemphigus |
| 126950026 | 12695002 | 11 | Pemphigus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126950026 | 12695002 | DE |
| 126950026 | 12695002 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126950026 | 12695002 | Cataract | |
| 126950026 | 12695002 | Dermatitis bullous | |
| 126950026 | 12695002 | Diabetes mellitus | |
| 126950026 | 12695002 | Hepatic function abnormal | |
| 126950026 | 12695002 | Multiple organ dysfunction syndrome | |
| 126950026 | 12695002 | Muscle disorder | |
| 126950026 | 12695002 | Pancreatic carcinoma |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |